Public Joint-Stock Company "Human Stem Cells Institute"

Public Joint-Stock Company "Human Stem Cells Institute" Acción · RU000A0JNAB6 (MISX) — cotizaciones en tiempo real, datos de la empresa, dividendos, fundamentales y análisis de cartera con IA en MoneyPeak

Resumen
Análisis impulsado por IA
Análisis fundamental
Descubre lo que realmente dicen los números — antes que el mercado
Analizar ahora
Sentimiento de noticias
¿Las noticias de hoy son una señal de compra o una alerta?
Analizar ahora
Comprar / Mantener / Vender
¿Comprar, mantener o vender? Obtén el veredicto de la IA ahora.
Analizar ahora
Evaluación de riesgos
Descubre riesgos ocultos antes de que afecten a tu cartera.
Analizar ahora
Valor justo
¿Esta acción está barata, correctamente valorada o sobrevalorada?
Analizar ahora
Últimos análisis de IA sobre Public Joint-Stock Company "Human Stem Cells Institute"
Sin cotización
Precio de cierre MISX 01.05.2026: 58,10 RUB
01.05.2026 15:55
Cotizaciones actuales de Public Joint-Stock Company "Human Stem Cells Institute"
BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
MISX: MOEX
MOEX
ISKJ.ME
RUB
01.05.2026 15:55
58,10 RUB
0,46 RUB
+0,80 %
Flotación y Liquidez de las Acciones
Flotación Libre 5,72 %
Acciones en Flotación 4,67 M
Acciones en Circulación 81,61 M
Perfil de la empresa para Public Joint-Stock Company "Human Stem Cells Institute" Acción
Public Joint-Stock Company 'Human Stem Cells Institute' operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation. The company also offers Neovasculgen, a gene-therapy drug for treatment of peripheral arterial disease, including critical limb ischemia; and SPRS-therapy (service for personal regeneration of skin), a set of personalized diagnostics and treatment procedures for repairing skin damages. In addition, it operates GENETICO, a medical genetics center and molecular diagnostic lab that provides a range of genetic analysis and counseling services for the early detection, prediction, and prophylactic treatment of genetic disorders, including reproductive system diseases; and provides preimplantation genetic diagnosis and screening that includes testing of developing embryos for monogenic inherited diseases and chromosome abnormalities during an in vitro fertilization cycle. Further, the company offers non-invasive prenatal testing of fetal chromosome abnormalities; and develops Gemacell, a cell-based drug candidate for treatment of myocardial infarction. Additionally, it provides range of diagnostic services for identification of genetic predisposition to oncological diseases; and distributes cell processing equipment. The company was founded in 2003 and is based in Moscow, Russia. Public Joint-Stock Company 'Human Stem Cells Institute' is a subsidiary of PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy.

Datos de la empresa

Nombre Public Joint-Stock Company "Human Stem Cells Institute"
Empresa Public Joint-Stock Company "Human Stem Cells Institute"
Sitio web https://hsci.ru
Mercado principal MISX MOEX
ISIN RU000A0JNAB6
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Artur Alexandrovich Isaev
Capitalización de mercado 5 Mrd.
País Federación Rusa
Moneda RUB
Empleados -
Dirección 18/1 Olimpiysky prospect, 129110 Moscow
Fecha de OPV 2010-03-03
Dividendos de 'Public Joint-Stock Company "Human Stem Cells Institute"'
Fecha ex-dividendo Dividendo por acción
17.06.2024 94,00 RUB
18.07.2023 78,34 RUB
29.06.2016 23,50 RUB
27.06.2014 11,75 RUB
26.04.2010 7,83 RUB

Símbolos de cotización

Nombre Símbolo
MOEX ISKJ.ME
Otras acciones
Los inversores que tienen Public Joint-Stock Company "Human Stem Cells Institute" también tienen las siguientes acciones en su cartera:
PERPETUA RESOURCES CORP
PERPETUA RESOURCES CORP Acción
WinVest Acquisition Corp. - Common Stock
WinVest Acquisition Corp. - Common Stock Acción